Twist Bioscience Corp: STATE STREET CORP discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
State Street Corp disclosed a stake exceeding 5% in Twist Bioscience Corp via a Schedule 13G filing with the SEC (accession 0000093751-26-000733). The filing signals that State Street has crossed the 5% beneficial ownership threshold in the synthetic DNA and genomics company, making it a reportable large shareholder. The exact share count and percentage were not specified in the headline disclosure. The move matters because 13G filings are closely watched for signs of institutional accumulation in small- and mid-cap biotech names. Next, investors will look to the full filing for precise ownership figures and any subsequent 13G amendments reflecting changes in State Street's position.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
State Street Corp, Twist Bioscience Corp